The new formulation of Keytruda, currently under FDA review, is sparking conflict with Halozyme, which makes enzymes that ...

Novo Nordisk's NovoCare will now provide uninsured or underinsured patients access to Wegovy for just $499 per month—less ...

Merck’s Keytruda holds on to the top spot while AbbVie’s Humira—once the world’s top-selling drug—continues to cede its ...

At the heart of the deal is the drug candidate dordaviprone, which is months away from a regulatory verdict for its use in H3 ...

The vaccine space has been battered by strong headwinds in recent weeks, including high-level disruptions to FDA and CDC ...

A BioSpace analysis of all 80 priority review vouchers that have been handed out across the three FDA programs that offer ...

Acelyrin and Alumis plan to close their merger in the second quarter of 2025, pending clearances and shareholder approval.

The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...

Konstantina Katcheves, Senior VP of Innovative Global Business Development at Teva Pharmaceuticals brings insights from the ...

Pfizer reacts to Donald Trump’s tariff threats on big pharma, another regulatory meeting is canceled under RFK Jr., AbbVie ...

Congress did not reauthorize the rare pediatric disease priority review program at the end of 2024. Advocates say the ripple effect is already being felt across biopharma.

Less than two months after two FDA-related setbacks, Atara Biotherapeutics is again cutting its workforce in half. This time, ...